Core one aktie. Core One Labs Inc.: Core One Labs Signs Letter of Intent to Sell Certain Assets

These statements reflect management's current estimates, beliefs, intentions and expectations Joel Shacker Chief Executive Officer FOR MORE INFORMATION, PLEASE CONTACT: info core1labs
ET and the After Hours Market 4:00-8:00 p In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act Canada and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act Canada without a prescription or authorization
By adapting our existing technology to become an effective and safe delivery method for psilocybin, Core One has the ability to become a leader in this space," said Joel Shacker CEO of the company SOURCE: Core One Labs Inc
These websites are subject to the liability of the respective operators The acquisition of Vocan is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange
Core One Labs does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks Core One Labs Inc
Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect : Core One Labs Applauds TheraPsil on Its Submission to Health Canada 13
Health Canada has not approved psilocybin as a drug for any indication KG reviewed the third-party content for legal violations
Core One has successfully engaged in negotiations to sell off non-core assets of the business, allowing it to focus on entering the psychedelic space and the continued development of its CannaStrip TM technology They are not guarantees of future performance

Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations.


Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Hancock, chief executive officer and chairman of Vocan, is a leading researcher at the University of British Columbia, a Killam professor of microbiology and immunology, and a Canada Research chair in health and genomics.

This website may not be presented in third-party frames without permission.